PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
15.84%
Revenue growth 1.25-1.5x META's 12.29%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
16.05%
Gross profit growth 1.25-1.5x META's 12.33%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
17.08%
EBIT growth above 1.5x META's 10.27%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
17.08%
Operating income growth similar to META's 16.44%. Walter Schloss would assume both share comparable operational structures.
17.35%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
17.65%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
17.65%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
0.42%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.98%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
22.18%
OCF growth above 1.5x META's 6.39%. David Dodd would confirm a clear edge in underlying cash generation.
-53.92%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
3211.46%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
279.17%
5Y revenue/share CAGR 1.25-1.5x META's 190.49%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
69.87%
3Y revenue/share CAGR similar to META's 77.04%. Walter Schloss would assume both companies experience comparable short-term cycles.
No Data
No Data available this quarter, please select a different quarter.
361.70%
5Y OCF/share CAGR at 50-75% of META's 653.02%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
102.29%
3Y OCF/share CAGR at 75-90% of META's 125.05%. Bill Ackman would press for improvements in margin or overhead to catch up.
4068.40%
Net income/share CAGR 1.25-1.5x META's 2770.56%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
489.04%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
104.76%
3Y net income/share CAGR 50-75% of META's 194.47%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
323.26%
5Y equity/share CAGR above 1.5x META's 101.78%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
97.98%
3Y equity/share CAGR 1.25-1.5x META's 66.56%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.00%
AR growth is negative/stable vs. META's 14.10%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
87.68%
Inventory growth of 87.68% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
8.45%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.37%
Similar to META's 5.80%. Walter Schloss finds parallel capital usage or profit distribution strategies.
63.29%
Debt growth far above META's 0.08%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
5.73%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
22.46%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.